Takefumi Komiya, MD, PhD - Penn State Cancer Institute
Researcher Profile
Takefumi Komiya, MD, PhD
Associate Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Clinical Trials
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Recent Publications
2025
Hashinokuchi, A, Takamori, S, Takenaka, T, Yoshizumi, T & Komiya, T 2025, 'ASO Author Reflections: Impact of Primary Tumor Size in Thymic Epithelial Tumor', Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16827-z
2024
KEYNOTE-671 Investigators 2024, 'Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, vol. 404, no. 10459, pp. 1240-1252. https://doi.org/10.1016/S0140-6736(24)01756-2
Hashinokuchi, A, Takamori, S, Zhu, J, Abe, M, Ozono, K, Takenaka, T, Osoegawa, A, Yoshizumi, T & Komiya, T 2024, 'Prognostic Impact of Primary Tumor Size in Thymic Epithelial Tumor: An NCDB-Based Study', Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16732-5
Vazquez-Urrutia, JR, Greenberg, M, Zhu, J, Takamori, S & Komiya, T 2024, 'Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer', World Journal of Oncology, vol. 15, no. 5, pp. 769-776. https://doi.org/10.14740/wjon1924
Takamori, S, Osoegawa, A, Hashinokuchi, A, Karashima, T, Takumi, Y, Abe, M, Yamaguchi, M, Takenaka, T, Yoshizumi, T, Zhu, J & Komiya, T 2024, 'Role of Pathologic Single-Nodal and Multiple-Nodal Descriptors in Resected Non-Small Cell Lung Cancer', CHEST, vol. 166, no. 5, pp. 1218-1228. https://doi.org/10.1016/j.chest.2024.06.3797
Takamori, S, Zhu, J, Hashinokuchi, A & Komiya, T 2024, 'The Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-Small-Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database', Cancers, vol. 16, no. 12, 2176. https://doi.org/10.3390/cancers16122176
2023
Takamori, S, Shimokawa, M & Komiya, T 2023, 'Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer', Journal of Cancer Research and Clinical Oncology, vol. 149, no. 14, pp. 13175-13184. https://doi.org/10.1007/s00432-023-05167-2
Khan, SS & Komiya, T 2023, 'Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials', Asian Pacific Journal of Cancer Prevention, vol. 24, no. 1, pp. 331-336. https://doi.org/10.31557/APJCP.2023.24.1.331
Komiya, T, Takamori, S & Shimokawa, M 2023, 'Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer', World Journal of Oncology, vol. 14, no. 4, pp. 234-245. https://doi.org/10.14740/wjon1625
Takamori, S, Komiya, T, Shimokawa, M & Powell, E 2023, 'Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm', General Thoracic and Cardiovascular Surgery, vol. 71, no. 3, pp. 189-197. https://doi.org/10.1007/s11748-022-01876-6
2022
Komiya, T, Takamori, S & Wilding, G 2022, 'Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy', Radiotherapy and Oncology, vol. 176, pp. 234-238. https://doi.org/10.1016/j.radonc.2022.07.018
Sama, S, Komiya, T & Guddati, AK 2022, 'Advances in the Treatment of Mucoepidermoid Carcinoma', World Journal of Oncology, vol. 13, no. 1. https://doi.org/10.14740/wjon1412
Takamori, S, Komiya, T & Powell, E 2022, 'Clinical impact of number of lymph nodes dissected on postoperative survival in node-negative small cell lung cancer', Frontiers in Oncology, vol. 12, 962282. https://doi.org/10.3389/fonc.2022.962282
Dasari, S & Komiya, T 2022, 'Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series', Asian Pacific Journal of Cancer Prevention, vol. 23, no. 1, pp. 217-220. https://doi.org/10.31557/APJCP.2022.23.1.217
Komiya, T, Takamori, S & Wilding, G 2022, 'Response to Bao et al', Radiotherapy and Oncology, vol. 177, pp. 251. https://doi.org/10.1016/j.radonc.2022.10.031
2021
Jabbour, SK, Lee, KH, Frost, N, Breder, V, Kowalski, DM, Pollock, T, Levchenko, E, Reguart, N, Martinez-Marti, A, Houghton, B, Paoli, JB, Safina, S, Park, K, Komiya, T, Sanford, A, Boolell, V, Liu, H, Samkari, A, Keller, SM & Reck, M 2021, 'Pembrolizumab plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial', JAMA Oncology, vol. 7, no. 9, pp. 1351-1359. https://doi.org/10.1001/jamaoncol.2021.2301
Komiya, T, Powell, E & Takamori, S 2021, 'Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC', JTO Clinical and Research Reports, vol. 2, no. 3, 100111. https://doi.org/10.1016/j.jtocrr.2020.100111
Takamori, S, Shimokawa, M & Komiya, T 2021, 'Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients', Thoracic Cancer, vol. 12, no. 21, pp. 2943-2948. https://doi.org/10.1111/1759-7714.14178
Komiya, T, Ravindra, N & Powell, E 2021, 'Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung', Asian Pacific Journal of Cancer Prevention, vol. 22, no. 2, pp. 365-370. https://doi.org/10.31557/APJCP.2021.22.2.365
Komiya, T, Powell, E & Takamori, S 2021, 'Role of thoracic radiation in extensive stage small cell lung cancer: a NCDB analysis', Medical Oncology, vol. 38, no. 4, 44. https://doi.org/10.1007/s12032-021-01489-8
Bardia, A, Messersmith, WA, Kio, EA, Berlin, JD, Vahdat, L, Masters, GA, Moroose, R, Santin, AD, Kalinsky, K, Picozzi, V, O'Shaughnessy, J, Gray, JE, Komiya, T, Lang, JM, Chang, JC, Starodub, A, Goldenberg, DM, Sharkey, RM, Maliakal, P, Hong, Q, Wegener, WA, Goswami, T & Ocean, AJ 2021, 'Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial', Annals of Oncology, vol. 32, no. 6, pp. 746-756. https://doi.org/10.1016/j.annonc.2021.03.005
Takamori, S, Komiya, T & Powell, E 2021, 'Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis', Cancer medicine, vol. 10, no. 3, pp. 923-932. https://doi.org/10.1002/cam4.3675